^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR C797S |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
Published date:
01/18/2023
Excerpt:
Chest computed tomography (CT) showed nodules in the upper lobe of the left lung, and the patient was ultimately diagnosed with left lung adenocarcinoma (T4N1M1). The patient carried EGFR exon 19 deletion...NGS was performed (with plasma), and the EGFR C797S mutation was revealed....the patient commenced treatment with anlotinib at 12 mg/day combined with osimertinib 80 mg/day....Chest CT performed on December 16, 2021 showed stable SD. A CT (2022/1/17) image showed disease progression, and the patient was excluded from the clinical group. The patient’s PFS was 7 months after anlotinib treatment in addition to the regimen...
DOI:
https://doi.org/10.1016/j.phrs.2023.106668
